Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) rose 10.8% on Tuesday . The company traded as high as $10.86 and last traded at $10.54. Approximately 41,619 shares were traded during mid-day trading, a decline of 91% from the average daily volume of 467,094 shares. The stock had previously closed at $9.51.
Wall Street Analysts Forecast Growth
Several analysts recently weighed in on BCAX shares. Stifel Nicolaus set a $48.00 price objective on Bicara Therapeutics in a research report on Thursday, March 27th. HC Wainwright reduced their price target on shares of Bicara Therapeutics from $45.00 to $44.00 and set a "buy" rating on the stock in a research note on Monday, April 7th. Cantor Fitzgerald reissued an "overweight" rating and issued a $13.01 price objective on shares of Bicara Therapeutics in a research note on Thursday, March 13th. Finally, Wedbush restated an "outperform" rating and issued a $31.00 target price on shares of Bicara Therapeutics in a research report on Thursday, March 27th. Seven investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Bicara Therapeutics has an average rating of "Buy" and an average target price of $36.50.
Get Our Latest Research Report on Bicara Therapeutics
Bicara Therapeutics Trading Up 6.1 %
The company has a fifty day simple moving average of $12.76 and a 200 day simple moving average of $16.82.
Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.39) EPS for the quarter, missing analysts' consensus estimates of ($0.31) by ($0.08). Equities analysts anticipate that Bicara Therapeutics Inc. will post -2.59 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Bicara Therapeutics
Hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System bought a new stake in Bicara Therapeutics during the fourth quarter valued at $25,000. Spire Wealth Management acquired a new stake in Bicara Therapeutics during the fourth quarter worth approximately $31,000. BNP Paribas Financial Markets bought a new stake in Bicara Therapeutics in the fourth quarter worth approximately $32,000. Legal & General Group Plc acquired a new position in Bicara Therapeutics in the fourth quarter valued at approximately $33,000. Finally, Summit Investment Advisors Inc. bought a new position in shares of Bicara Therapeutics during the 4th quarter worth approximately $35,000.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.
Featured Stories
Before you consider Bicara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bicara Therapeutics wasn't on the list.
While Bicara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
